CMIC and SUSMED to Collaborate on Providing Digital Therapeutics Development Services

CMIC, a Japanese contract research organization (CRO), and SUSMED, a research and development firm also located in Japan, announced on Oct. 21, 2020 that they have formed a strategic partnership to offer digital therapeutics (DTx) development services from app development to post-launch support.

According to a CMIC press release, the companies will work to provide development strategy consultations, system-building, and clinical trial operations, while lessening development time and reducing risk by centralizing project tasks between companies. The services will be available to pharmaceutical and information technology companies in Japan and worldwide.

“DTx will be an important field in the Japanese healthcare industry going forward, and it is a new market for which regulations and other infrastructure are just starting to be established,” said Toru Fujieda, president of CMIC, in the press release. “SUSMED shares the same pioneering spirit as CMIC to work outside the box. With this partnership we are now able to combine our knowledge in various areas to build and offer an integrated DTx service platform that covers all steps from development to post-launch support. It will support the continuous growth of the DTx market and help advance the healthcare industry in Japan.”

“Leveraging this partnership with CMIC, we can provide our technology to a larger number of companies and help accelerate the overall DTx market growth in Japan,” said Taro Ueno, CEO of SUSMED, in the press release. “We believe that building this one-stop service platform will allow us to deliver more treatment approaches to healthcare providers in Japan.”

Source:​ CMIC​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​